Ophtec Secures CE Marking for Aspheric Presbyopia-Correcting IOL

May 12, 2017: By Jon Swedien

OphtecOphtec has received CE marking for its Precizon Presbyopic, a new aspheric presbyopia-correcting IOL, the Netherlands company announced May 6.

The lens will be commercially launched in October 2017 during the annual conference of the European Society of Cataract and Refractive Surgeons in Lisbon, Portugal.

The product will initially be available in the European Union and a few selected markets, Ophtec said.

The Precizon Presbyopic IOL features a patent-pending continuous transitional focus (CTF) optical design.

The CTF design’s transitional zones offer a smooth, continuous transition from near to infinity vision, enabling surgeons to treat a wider range of presbyopic patients with confidence, Ophtec said.

The IOL appears to be able to forgive larger degrees of lens tilt and decentration, and this tolerance reduces photic phenomena, helping patients to adapt more naturally to their new vision, Ophtec said.

The lens is also designed to be less dependent on pupil size under all lighting conditions, Ophtec said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023